HR-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics: Targeted therapies for ER-positive breast cancer (0:00) Clinical data with oral selective estrogen receptor degraders (2:13) Biological rationale for and mechanism of action of proteolysis-targeting chimeras (PROTACs) (7:07) Emerging data with PROTACs for ER-positive advanced breast cancer (9:17) Future directions with PROTACs for breast cancer (19:21) CME information and select publications